Part 7/10:
Todd explained that the FDA generally requires robust evidence of efficacy from multiple trials before approving a drug, and Alchemy had only demonstrated sufficient results in one of three trials. This illustrates the high stakes surrounding drug approval processes in pharma, as the failures can lead to significant financial implications for the companies involved.